Rocket Pharmaceuticals, Inc. (RCKT) financial statements (2021 and earlier)
Company profile
| Business Address |
350 FIFTH AVENUE NEW YORK, NY 10118 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| SIC | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in millions)
| 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | |||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash, cash equivalents, and short-term investments, including: | 483 | 304 | 213 | 100 | 126 | 111 | ||
| Cash and cash equivalents | 297 | 185 | 111 | 79 | 30 | 80 | ||
| Short-term investments | 186 | 119 | 94 | 21 | 97 | 31 | ||
| Other undisclosed cash, cash equivalents, and short-term investments | (0) | (0) | 7 | |||||
| Deferred costs | 2 | |||||||
| Other undisclosed current assets | 5 | 4 | (4) | 1 | 2 | (1) | ||
| Total current assets: | 487 | 308 | 209 | 101 | 128 | 112 | ||
| Noncurrent Assets | ||||||||
| Finance lease, right-of-use asset | 51 | ✕ | ✕ | ✕ | ✕ | |||
| Operating lease, right-of-use asset | 1 | 2 | ✕ | ✕ | ✕ | ✕ | ||
| Property, plant and equipment | 19 | 29 | 2 | 1 | 1 | 1 | ||
| Long-term investments and receivables | 7 | |||||||
| Long-term investments | 7 | |||||||
| Intangible assets, net (including goodwill) | 31 | 31 | 31 | |||||
| Goodwill | 31 | 31 | 31 | |||||
| Deposits noncurrent assets | 0 | 0 | 1 | |||||
| Restricted cash and investments | 2 | 2 | 1 | |||||
| Other noncurrent assets | 0 | 0 | 0 | |||||
| Other undisclosed noncurrent assets | 0 | |||||||
| Total noncurrent assets: | 103 | 64 | 42 | 1 | 1 | 1 | ||
| TOTAL ASSETS: | 591 | 372 | 251 | 102 | 130 | 113 | ||
| LIABILITIES AND EQUITY | ||||||||
| Liabilities | ||||||||
| Current Liabilities | ||||||||
| Accounts payable and accrued liabilities, including: | 25 | 17 | 15 | 4 | 7 | 4 | ||
| Accounts payable | 1 | 4 | 0 | 2 | 2 | |||
| Accrued liabilities | 2 | 1 | 1 | 2 | 4 | 3 | ||
| Employee-related liabilities | 5 | 3 | 2 | |||||
| Interest and dividends payable | 1 | 1 | 1 | 1 | 1 | |||
| Other undisclosed accounts payable and accrued liabilities | 16 | 8 | 11 | |||||
| Debt | 7 | 1 | ||||||
| Other undisclosed current liabilities | 1 | |||||||
| Total current liabilities: | 33 | 18 | 15 | 4 | 7 | 4 | ||
| Noncurrent Liabilities | ||||||||
| Long-term debt and lease obligation | 55 | 46 | 41 | |||||
| Long-term debt, excluding current maturities | 35 | 45 | 41 | |||||
| Finance lease, liability | 19 | ✕ | ✕ | ✕ | ✕ | |||
| Operating lease, liability | 0 | 1 | ✕ | ✕ | ✕ | ✕ | ||
| Liabilities, other than long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Deferred rent credit | 0 | ✕ | ✕ | ✕ | ||||
| Other liabilities | 0 | 0 | 0 | 0 | 0 | |||
| Other undisclosed noncurrent liabilities | 50 | 49 | ||||||
| Total noncurrent liabilities: | 55 | 47 | 42 | 50 | 49 | 0 | ||
| Total liabilities: | 87 | 65 | 57 | 54 | 56 | 5 | ||
| Stockholders' equity | ||||||||
| Stockholders' equity attributable to parent | 504 | 307 | 194 | 48 | 73 | 109 | ||
| Common stock | 1 | 1 | 0 | 0 | 0 | 0 | ||
| Treasury stock, value | (0) | (1) | ||||||
| Additional paid in capital | 826 | 490 | 300 | 316 | 312 | 305 | ||
| Accumulated other comprehensive income (loss) | (0) | 0 | (0) | (0) | (0) | (0) | ||
| Accumulated deficit | (323) | (183) | (106) | (268) | (239) | (196) | ||
| Total stockholders' equity: | 504 | 307 | 194 | 48 | 73 | 109 | ||
| TOTAL LIABILITIES AND EQUITY: | 591 | 372 | 251 | 102 | 130 | 113 | ||
Income statement (P&L) ($ in millions)
| 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | ||
|---|---|---|---|---|---|---|---|
| Operating expenses | (134) | (76) | (71) | (27) | (42) | (20) | |
| Operating loss: | (134) | (76) | (71) | (27) | (42) | (20) | |
| Nonoperating income (Investment Income, Nonoperating) | 1 | 0 | 0 | ||||
| Interest and debt expense | (7) | (6) | (6) | (4) | (1) | (1) | |
| Net loss: | (141) | (82) | (77) | (29) | (43) | (22) | |
| Other undisclosed net income (loss) attributable to parent | 2 | 5 | 3 | (46) | |||
| Net loss attributable to parent: | (140) | (77) | (75) | (29) | (43) | (68) | |
| Preferred stock dividends and other adjustments | (0) | ||||||
| Net loss available to common stockholders, diluted: | (140) | (77) | (75) | (29) | (43) | (68) | |
Comprehensive Income ($ in millions)
| 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | ||
|---|---|---|---|---|---|---|---|
| Net loss: | (141) | (82) | (77) | (29) | (43) | (22) | |
| Other undisclosed comprehensive income (loss) | 0 | (0) | (46) | ||||
| Comprehensive loss: | (141) | (82) | (77) | (29) | (43) | (68) | |
| Other undisclosed comprehensive income, net of tax, attributable to parent | 2 | 5 | 3 | ||||
| Comprehensive loss, net of tax, attributable to parent: | (140) | (77) | (75) | (29) | (43) | (68) | |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.